Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA

Back

Angiotensin Peptides and Lung Cancer

Author(s): P. E. Gallagher, K. Cook, D. Soto-Pantoja, J. Menon and E. A. Tallant

Affiliation: Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.

Keywords: Renin-angiotensin system, angiotensin, lung cancer, pulmonary cancer, angiotensin-(1-7), angiotensin converting enzyme, angiogenesis, angiotensin receptor blocker, Angiotensin Peptides, plasminogen activated inhibitor, –, 1, vascular endothelial growth factor, cyclooxygenase 2

Abstract:

Lung cancer is a leading cause of death in both men and women, with over 1,000,000 new cases diagnosed worldwide annually and a 5-year survival rate of only 14%, a figure that has improved little in the past thirty years. This poor prognosis suggests a need for novel approaches for the treatment and prevention of lung cancer. The reninangiotensin system is an established, primary regulator of blood pressure, homeostasis, and natriuresis; however, compelling evidence indicates that the angiotensin peptides also play a role in cell proliferation and inflammation. Angiotensin II is a vasoconstrictor, a mitogen, and an angiogenic factor, while angiotensin-(1-7) has vasodilator, antiproliferative, and anti-angiogenic properties. This review focuses on studies examining the renin-angiotensin system in pulmonary cancers and whether clinical intervention of this pathway may serve as an effective chemotherapeutic and/or chemopreventive modality for lung cancer.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 11
ISSUE: 4
Page: [394 - 404]
Pages: 11
DOI: 10.2174/156800911795538048